Evidence map›Paper›PMID 39242213›Full record

ArticleACS chemical neuroscience2024

Reversible Control of Native GluN2B-Containing NMDA Receptors with Visible Light.

Chloé Geoffroy, Romain Berraud-Pache, Nicolas Chéron, Isabelle McCort-Tranchepain, Julia Doria, Pierre Paoletti, Laetitia Mony

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chloé GeoffroyInstitut de Biologie de l'Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, CNRS, INSERM, Université PSL, Paris F-75005, France.
Romain Berraud-PacheLaboratoire d'Archéologie Moléculaire et Structurale (LAMS), CNRS UMR 8220, Sorbonne Université, Paris 75005, France.
Nicolas ChéronPASTEUR, Département de chimie, École normale supérieure, CNRS, Université PSL, Sorbonne Université, Paris 75005, France.ORCID 0000-0002-4090-5897
Isabelle McCort-TranchepainLaboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS UMR8601, Université Paris Cité, Paris 75006, France.ORCID 0000-0001-7447-8806
Julia DoriaInstitut de Biologie de l'Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, CNRS, INSERM, Université PSL, Paris F-75005, France.ORCID 0009-0001-4324-5716
Pierre PaolettiInstitut de Biologie de l'Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, CNRS, INSERM, Université PSL, Paris F-75005, France.
Laetitia MonyInstitut de Biologie de l'Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, CNRS, INSERM, Université PSL, Paris F-75005, France.ORCID 0000-0001-7753-6231

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NMDA receptors (NMDARs) are glutamate-gated ion channels playing a central role in synaptic transmission and plasticity. NMDAR dysregulation is linked to various neuropsychiatric disorders. This is particularly true for GluN2B-containing NMDARs (GluN2B-NMDARs), which have major pro-cognitive, but also pro-excitotoxic roles, although their exact involvement in these processes remains debated. Traditional GluN2B-selective antagonists suffer from slow and irreversible effects, limiting their use in native tissues. We therefore developed OptoNAM-3, a photoswitchable negative allosteric modulator selective for GluN2B-NMDARs. OptoNAM-3 provided light-induced reversible inhibition of GluN2B-NMDAR activity with precise temporal control both in vitro and in vivo on the behavior of freely moving

Indexed as

LightReceptors, N-Methyl-D-AspartateAnimalsAzo CompoundsHumansLarvaXenopusXenopus laevisazobenzeneAzo CompoundsNR2B NMDA receptorReceptors, N-Methyl-D-AspartateallosteryazobenzenesGluN2B-selective antagonistsglutamateNMDA receptorsoptopharmacology

Identifiers

PMID39242213
PMCPMC11413854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.